[Urinary excretion of glycine.prolile dipeptidile aminopeptidase, N-acetyl-beta-D-glucosaminidase, alanine aminopeptidase and low molecular protein in patients with renal cell carcinoma].
Urinary excretion of glycine.prolile dipeptidile aminopeptidase (GP-DAP), N-acetyl-beta-D-glucosaminidase (NAG), alanine aminopeptidase (AAP) and beta 2-microglobulin (beta 2-M), alpha 1-microglobulin (alpha 1-M) was studied preoperatively in 32 patients with renal cell carcinoma. The excretion indices of GP-DAP, AAP and NAG were significantly higher than those in the healthy control group. The excretion of these enzymes obviously reflected the degree of the tumor progression. However, positive rates were not remarkable (37% for GP-DAP, 37% for AAP and 28% for NAG). The excretion of beta 2-M and alpha 1-M was not increased in renal cell carcinoma patients.
Kitamura
Y
Y
Department of Urology, Niigata Cancer Center Hospital.
Watanabe
M
M
Komatsubara
S
S
Sakata
Y
Y
D000118:Acetylglucosaminidase / Q000652:urine*; D000328:Adult; D000510:Alpha-Globulins / Q000652:urine; D000626:Aminopeptidases / Q000652:urine*; D014408:Biomarkers, Tumor / Q000652:urine*; D018826:CD13 Antigens; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000652:urine*; D004796:Clinical Enzyme Tests; D018819:Dipeptidyl Peptidase 4; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000652:urine*; D006596:Hexosaminidases / Q000652:urine*; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000652:urine*; D008970:Molecular Weight; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D012712:Serum Globulins / Q000652:urine*; D001613:beta 2-Microglobulin / Q000652:urine
D000510:Alpha-Globulins; D014408:Biomarkers, Tumor; D012712:Serum Globulins; C016001:alpha-1-microglobulin; D001613:beta 2-Microglobulin; D006596:Hexosaminidases; D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; D018819:Dipeptidyl Peptidase 4